Guidance IncreaseCRMD increased its 2025 pro-forma net revenue guidance to at least $375 million, driven by current DefenCath sales and performance of the Melinta portfolio.
Product LaunchRezzayo's launch has looked promising, gaining formulary placement at over 40 health systems and adoption across more than 330 accounts since launch.
Revenue GrowthCRMD reported preliminary third-quarter revenues of at least $100 million, significantly ahead of the Street's $65.9 million, due to stronger than expected DefenCath sales.
Strategic InvestmentCRMD made a $5MM equity investment in Talphera, which is developing Niyad as an anticoagulant, providing CRMD with the first right of negotiation to acquire Talphera.